229 results on '"Schüpke, Stefanie"'
Search Results
2. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel
3. High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
4. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
5. Índice de masa corporal y eficacia y seguridad del ticagrelor frente al prasugrel en pacientes con síndrome coronario agudo
6. Optimal sample size allocation for two‐arm superiority and non‐inferiority trials with binary endpoints
7. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes
8. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus
9. Sex differences in the outcome after percutaneous coronary intervention – A propensity matching analysis
10. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention.
11. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials
12. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention
13. Peri- and Post-procedural Antithrombotic Therapy in Women
14. Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions
15. Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
16. Präoperative klinische Risikoeinschätzung
17. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
18. The role of bivalirudin in percutaneous coronary intervention
19. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial
20. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes
21. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy
22. Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women: Gender-Based Analysis of a Large Scale, Randomized Clinical Trial
23. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
24. Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y12 Inhibitor Thereafter
25. Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial
26. Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes—a subgroup analysis of the ISAR-REACT 5 trial
27. Peri- and Post-procedural Antithrombotic Therapy in Women
28. Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
29. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome
30. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention
31. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate
32. Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial
33. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
34. Assessing the Benefit of Vascular Closure Devices After Femoral Artery Puncture—Reply
35. Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture: The ISAR-CLOSURE Randomized Clinical Trial
36. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease
37. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention
38. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
39. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: A Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
40. Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population
41. Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients
42. Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
43. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes
44. Gender balance at the heart of science
45. Randomized Comparison of Intensified and Standard P2Y 12 -Receptor-Inhibition Before Elective Percutaneous Coronary Intervention
46. Radiation protection measures and sex distribution in European interventional catheterisation laboratories
47. Chronisches und akutes Koronarsyndrom
48. Resultado del tratamiento percutáneo de la reestenosis de stents farmacoactivos: ¿depende de si el stent tenía o no recubrimiento polimérico?
49. Acute Coronary Syndromes and the Nontarget Lesion
50. Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.